Big Pharma is running scared …
For over a decade, new biotech-powered medicines and therapies have been threatening some of their longest-standing (and most profitable) products.
Consumers are becoming more and more aware of the side effects of their drugs too. And “it scares the crap out of the pharmaceutical companies,”2 according to one expert. People are growing increasingly frustrated with the cost of “managing” their health issues with prescriptions—sometimes even having to take one drug to offset the harmful side effects of yet another drug.
The result is a radically transforming landscape, with the Biotech market expected to soar to $2.44 Trillion in the next 7 years3. In that time, new disruptive innovators will rise to dominance—and some of today’s most lucrative medical therapies will become obsolete overnight.
Emergent Health Corp. (OTC Pink:EMGE) might just be one of those companies … and their newest breakthrough might threaten $158 Billion of Big Pharma’s business1, each and every year …
America’s Deadliest Affliction
Cancer is the second most-prolific killer in the United States each year, just behind heart disease. In 2019, the Centers for Disease Control recorded 599,6014 total deaths from various forms of cancer.
Now you may want to take a seat for this…
According to the American Cancer Society, it’s estimated that 40% of all men (and 38% of all women) will be diagnosed with Cancer at some point in their lives. 5
As you can imagine, there are more different dr-ugs used to treat cancer than for any other type of affliction or condition:6
These medications are mostly used in chemotherapy or hormone therapy. And there’s more coming. Much more.
It’s estimated that 5,212 more anti-cancer dr-ugs are currently in Big Pharma’s “pipeline.”6 Talk about a cash cow!
By 2024, experts believe that $1 out of every $5 spent on prescription dr-ugs will go towards cancer medication.6 That’s an estimated $240 Billion each year in sales.
That might sound like “Great News” for Big Pharma. But in reality it’s a massive burden on those suffering from various afflictions, and many are looking for an alternative …
The “Forbidden” Alternative
Regenerative medicine is an increasingly popular new alternative to traditional treatments and therapies …
This treatment specifically focuses on repairing, re-growing, or re-generating damaged or diseased cells, organs or tissues—directly attacking the underlying cause of a condition instead of just treating the symptoms.7
Early studies indicate seriously positive results, but many of these new therapies have yet to obtain FDA approval; let alone compete with the billion-dollar business of Pfizer or Johnson & Johnson.
In fact, film star Mel Gibson shared his personal story with Joe Rogan about this Regenerative Medicine. This eye-opening video has been viewed over a million times on YouTube:
Emergent Health Corp (OTC Pink: EMGE) has been a trailblazer in Regenerative Medicine for over 15 years now. 8
Guided by their President and Founder, Dr. John V. Cappello, DO, and MBA, the company is a diversified biotechnology firm with a focus on developing health and wellness products with mass appeal. 9
Most recently, through their subsidiary Emergent Health Foods, the company has begun to develop new supplements like CancX®, a dietary supplement designed to provide crucial nutrition to those suffering from cancer and other debilitating conditions. 10
Whether undergoing therapy, in recovery, or in remission and just striving to avoid recurrence, it’s absolutely crucial to optimize caloric intake and nutritional quality in order to lessen side effects, reduce the risk of infection, and improve overall quality of life.
The company refers to it as “Nutrition Therapy,” and focuses on a few key goals with products like CancX®: 11
Medical Nutrition Therapy (or MNT for short), is already widely accepted by medical professionals as a “key component in diabetes education and management” according to the CDC.12
Emergent Health Corp.’s (OTC Pink: EMGE) breakthrough Nutrition Therapy products work on similar principles, with scientifically-proven ingredients combined to provide crucial dietary benefits for those suffering from cancer.
CancX® is a unique formulation based on proprietary patents and well-studied ingredients that can’t be found in practically any other supplement. It’s designed to deliver a comparatively large variety of Ellagitannins and Beta Glucans, with a blend of 24 vitamins and nutrients optimized to support energy, mood, sleep, appetite and strength.13
Ellagic acid is an increasingly popular anti-inflammatory compound that has been shown in studies by the Medical University of South Carolina to kill some cancer cells in laboratory experiments.14
The ellagitannins found in CancX®’s key ingredient (Red Raspberry Seed Powder) are powerful polyphenolic compounds rich in dietary fiber and proteins.13
These ingredients are combined with the goal of creating a more holistic alternative that can help to improve quality of life without the dangerous side effects or complications that arise from many prescription pharmaceuticals.
Early test results seem promising. In a press release from May of 2020,15 the company reported positive results on prospective research study. Over four weeks of trial usage, all participants reported multiple benefits—including improved alertness, better sleep, better mobility and improved appetite. When asked to rate CancX® on a scale of 1 to 10 in terms of effectiveness, all participants rated it between 8 and 10.
Dr. Jane Lock’s story about her experience with CancX® is especially compelling.
The company’s newest product, Anxium™ Stress Relief, is an all-natural patent pending stress relief product “designed to compete with dr-ugs like Valium, Klonepin, Vistaril and other prescription dr-ugs.”16
Shares Poised for a Comeback?
Emergent Health Corp (OTC Pink: EMGE) is debt-free16 and, at time of writing (11/16/21), the company is trading at roughly 72% off its 52-week highs. 17
The company admits that it’s struggled with management in recent years; which left the current team in the lurch with no business or assets back in 2016—after several years which saw cumulative sales reach $5 Million. 20
Now headed in a new direction thanks to the change in management, the company has invested a substantial portion of its resources into the development of their new subsidiary—Emergent Medical Foods—with a new “Consumer-Powered” business plan and a new networking website launched in the first half of 2020.
This new business will build a network of 100-20020 Advisory Physicians who will recommend the company’s products, backed by a network across the web and social media to bring new products like CancX® and Anxium™ to the people who need them the most.
Emergent Health Corp.’s (OTC Pink: EMGE) ultimate goal is to take the subsidiary public with a spinoff IPO at a target of $6 per share. 20
According to a press release from August of 2020, some of the company’s breakthrough supplements “literally have no known competition,” 20 thanks in part to the company’s portfolio of key (and pending) patents. 18
Just as important, this new direction means the company will be following in the footsteps of network marketing companies like HerbaLife (HLF), which has over 2,300,000 distributors and now trades at over $42 per share. 19
Even if shares simply retraced the company’s current all-time high, that would provide an estimated upside potential of 1,419% from today’s valuation (11/16/21). 17
Now, I’m not saying EMGE is going to run 1,419% to those past highs, but with the new management team working to improve transparency, working to uplist the company to OTCQB Venture Markets,20 and book revenue from their new subsidiary, it’s quite possible that Emergent Health Corp. (OTC Pink: EMGE) shares could be displaying some serious near-term upside potential.
List Of The Resources
This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
(Last updated: 05-26-2022 4:16:58)